NEW YORK (GenomeWeb) – Interpace Diagnostics reported today that its third quarter revenues rose 27 percent amid increased demand and reimbursement for its thyroid assays.

For the three-month period ended Sept. 30, Interpace's revenues climbed to $4.2 million from $3.3 million in the same period a year earlier. The company attributed the growth primarily to higher sales and reimbursement of its ThyGenX and ThyraMir tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.